Response to Comments: MolDX: Next Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

This document records responses to comments on LCD DL38123 (NGS LDTs for myeloid malignancies), noting the comment period (5/30/2019–7/15/2019), notice start (4/2/2020) and effective date (5/17/2020). It also notes that PGBA MolDx retired article A57503 and referenced A57757 for primary cancer definition, but that Noridian has not adopted or implemented A57757.

"Article A57757 (clarification of primary cancer definition) has not been adopted or implemented by Noridian and should not be treated as an implemented policy authority."

Sign up to see full coverage criteria, indications, and limitations.